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ABSTRACT
The repair of articular cartilage lesions remains a clinical problem. Two novel approaches to cartilage for-
mation, gene transfer and tissue engineering, have been limited by short-term transgene expression in trans-
planted chondrocytes and inability to deliver regulatory signals to engineered tissues according to specific
temporal and spatial patterns. We tested the hypothesis that the transfer of a cDNA encoding the human in-
sulin-like growth factor I (IGF-I) can provide sustained gene expression in cell–polymer constructs in vitro
and in vivo and enhance the structural and functional properties of tissue-engineered cartilage. Bovine artic-
ular chondrocytes genetically modified to overexpress human IGF-I were seeded into polymer scaffolds, cul-
tured in bioreactors in serum-free medium, and implanted subcutaneously in nude mice; constructs based on
nontransfected or lacZ-transfected chondrocytes served as controls. Transgene expression was maintained
throughout the duration of the study, more than 4 weeks in vitro followed by an additional 10 days either in
vitro or in vivo. Chondrogenesis progressed toward the formation of cartilaginous tissue that was character-
ized by the presence of glycosaminoglycans, aggrecan, and type II collagen, and the absence of type I colla-
gen. IGF-I constructs contained increased amounts of glycosaminoglycans and collagen and confined-com-
pression equilibrium moduli as compared with controls; all groups had subnormal cellularity. The amounts
of glycosaminoglycans and collagen per unit DNA in IGF-I constructs were markedly higher than in con-
structs cultured in serum-supplemented medium or native cartilage. This enhancement of chondrogenesis by
spatially defined overexpression of human IGF-I suggests that cartilage tissue engineering based on geneti-




The objective of the present study was to use sustained ex-
pression of a gene, the product of which has anabolic effects,
in a model system of cartilage tissue engineering. We report
experimental evidence supporting the hypothesis that 
spatially defined overexpression of a human IGF-I cDNA 
in articular chondrocytes can enhance chondrogenesis and 
improve the structural and functional properties of tissue-
engineered cartilage. Genetically modified cartilaginous
constructs may be applied for the repair of articular carti-
lage lesions and for controlled studies of factors and mech-
anisms involved in the regulation of chondrogenesis.
INTRODUCTION
THE INTRINSIC REPAIR of damaged articular cartilage is min-imal. Although a variety of methods currently exist to re-
pair cartilage lesions, none of them has been shown to pre-
dictably restore a durable articular surface (Buckwalter and
Mankin, 1998). The clinical need for improved treatment op-
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tions is being addressed by gene therapy (Evans and Robbins,
1999) and tissue engineering (Langer and Vacanti, 1993). These
two different approaches have each led to encouraging initial
results (Langer and Vacanti, 1993; Baragi et al., 1995; Kang et
al., 1997; Doherty et al., 1998; Evans and Robbins, 1999;
Madry and Trippel, 2000). Both approaches are also subject to
limitations, including short-term expression of transgenes in ar-
ticular chondrocytes (Baragi et al., 1995; Kang et al., 1997; Do-
herty et al., 1998; Madry and Trippel, 2000) and the inability
to deliver regulatory signals to cells in engineered tissues ac-
cording to specific temporal and spatial patterns (Saltzman,
1999).
Functional substitutes of native articular cartilage can be cre-
ated in vitro starting from chondrogenic cells attached to poly-
mer scaffolds in bioreactors, herein referred to as cartilaginous
cell–polymer constructs (Freed and Vunjak-Novakovic, 2000).
During this process, chondrocytes produce extracellular tissue
matrix consisting of proteoglycans and type II collagen in par-
allel with the scaffold degradation (Freed et al., 1998). The re-
sulting cartilaginous constructs are generally characterized by
subnormal structural and mechanical properties. For example,
after 6 weeks of culture cell–polymer constructs contain 75%
as much glycosaminoglycan and 40% as much collagen, and
have a confined-compression equilibrium modulus that is 4-fold
lower as compared with freshly explanted articular cartilage
(Vunjak-Novakovic et al., 1999).
Insulin-like growth factor I (IGF-I), a 7.6-kDa polypeptide
growth factor, has been shown to increase chondrocyte mitotic
activity and proteoglycan and type II collagen synthesis in vitro
(Trippel, 1997). It has been demonstrated that articular chon-
drocytes can be genetically modified (Baragi et al., 1995; Kang
et al., 1997; Doherty et al., 1998; Madry and Trippel, 2000) to
express recombinant IGF-I (Madry and Trippel, 2000; Smith et
al., 2000; Brower-Toland et al., 2001). Overexpression of hu-
man IGF-I stimulated synthesis of collagen and noncollagenous
proteins in chondrocytes in vitro (Smith et al., 2000; Brower-
Toland et al., 2001), and promoted new tissue formation in an
ex vivo model of articular chondrocyte transplantation (Madry
et al., 2001b). It remains unknown whether the chondrogene-
sis in tissue-engineered cartilaginous constructs can be modu-
lated by localized overexpression of human IGF-I.
In the present work, we tested the hypothesis that transgene
expression in genetically modified cartilaginous constructs is
maintained in vitro and after subcutaneous implantation in vivo,
and that the transfer of a human IGF-I cDNA augments the struc-
tural and functional properties of tissue-engineered cartilage.
MATERIALS AND METHODS
Model system
We engineered cartilaginous constructs by using bovine ar-
ticular chondrocytes that were (1) not modified (referred to as
nontransfected constructs), (2) genetically modified to overex-
press the Escherichia coli b-galactosidase (lacZ) gene (referred
to as lacZ constructs), or (3) genetically modified to overex-
press a human insulin-like growth factor I cDNA (referred to
as IGF-I constructs). These three groups of chondrocytes were
seeded onto biodegradable polymer scaffolds and cultured in
bioreactors in serum-free medium. The resulting constructs
were harvested after 10, 21, 28, and 38 days for structural and
functional assessment. After 28 days of cultivation, constructs
from each group were implanted subcutaneously in nude mice
for 10 days to verify the maintenance of gene expression in vivo
(Fig. 1).
Plasmid expression vectors
For overexpression of IGF-I, the human IGF-I plasmid ex-
pression vector pCMVhIGF-I was used. Bovine articular chon-
drocytes transfected with pCMVhIGF-I secrete significant lev-
els of bioactive human IGF-I protein (Madry et al., 2001b). For
expression of b-galactosidase, the plasmid expression vector
pCMVSportbGal (GIBCO-Life Technologies, Grand Island,
NY) was applied. Plasmids were subjected to endotoxin-free
maxipreparation (Qiagen, Hilden, Germany).
Cell culture, transfection, and seeding onto scaffolds
Chondrocytes were obtained from articular cartilage har-
vested from radiocarpal joints of 1- to 2-week-old calves (Trip-
pel et al., 1983). In each experiment, chondrocytes were 
isolated from pooled cartilage harvests from four to eight ra-
diocarpal joints, and placed in monolayer culture in growth
medium (Dulbecco’s modified Eagle’s medium [DMEM] with
ascorbic acid [50 mg/ml], penicillin G [100 U/ml], and strep-
tomycin [100 ml/ml] supplemented with 10% calf serum)
(GIBCO-Life Technologies) at 37°C in a humidified atmo-
sphere with 10% CO2. Chondrocytes were transfected after 2–3
days in culture, using the nonliposomal lipid preparation 
FuGENE 6 (Roche, Mannheim, Germany) with either
pCMVhIGF-I (IGF-I group), pCMVSportbGal (lacZ group), or
no vector (nontransfected group), and exposed to bovine tes-
ticular hyaluronidase (4 U/ml) 12 hr before and during trans-
fection (Madry and Trippel, 2000).
One day after transfection, chondrocytes were dissociated
from the culture plates, suspended in growth medium, and dy-
namically seeded onto polyglycolic acid scaffolds (53 2 mm
fibrous disks, 5 3 106 cells per scaffold) as previously de-
scribed (Vunjak-Novakovic et al., 1998). Aliquots of the cell
preparations that were used for seeding of the cell–polymer 
constructs were subjected to 5-bromo-4-chloro-3-indolyl-b-D-
galactopyranoside (X-Gal) staining to assess the success of the
transfection. The number of X-Gal-positive cells was between
25 and 40% on the basis of X-Gal staining of lacZ-transfected
chondrocytes, consistent with a previous study using the same
technique (Madry and Trippel, 2000).
After 2 days, cell–polymer constructs were transferred into
bioreactors. Rotating bioreactors were used (RCCV-110; Syn-
thecon, Houston, TX) and were configured as an annular space
between a 57.5-mm-diameter outer cylinder and a 20-mm-di-
ameter inner gas exchange membrane that rotates as a solid
body around its horizontal axis (Freed et al., 1998). The ves-
sel-rotating rate is adjusted such that each tissue construct is
freely suspended in the rotational flow (Freed and Vunjak-No-
vakovic, 2000). Over the course of tissue cultivation, the in-
crease in construct size and weight necessitated a gradual in-
crease in the rotation rate from 15 to 30 rpm in order to keep
the growing constructs freely suspended. Constructs (n 5 12
per vessel) were cultured in 120 ml of basal medium (DMEM
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with ascorbic acid [50 mg/ml], penicillin G [100 U/ml], and
streptomycin [100 ml/ml]) and sampled on days 10, 21, 28, and
38 posttransfection. Medium was replaced every 3 days (50%);
gas exchange was continuous.
RNA isolation and Northern analysis
Total cellular RNA was extracted from chondrocytes in
monolayer culture 8 days after transfection (RNeasy; Qiagen),
fractionated on 1% agarose gels, and transferred to nylon mem-
branes (Bio-Rad, Hercules, CA). After cross-linking of the
membranes and prehybridization, RNA was hybridized for 16
hr at 42°C to a human IGF-I or a bovine glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) cDNA probe labeled with
[32P]dCTP, using a random primer labeling kit (Stratagene, La
Jolla, CA). The final stringency of wash was 0.53 SSPE (13
SSPE is 0.18 M NaCl, 10 mM NaPO4, and 1 mM EDTA [pH
7.7])–0.5% sodium dodecyl sulfate (SDS) at 65°C.
Histology and immunohistochemistry
Constructs were fixed in 10% formalin for 24 hr, embedded
in paraffin, cut to 5 mm either en face or in cross-section, and
stained with safranin O to detect proteoglycans. To detect b-
galactosidase activity, constructs were fixed for 10 min in 10%
formalin and stained for 4–6 hr at 37°C for b-galactosidase (In
Situ b-galactosidase staining kit; Stratagene) (Madry and Trip-
pel, 2000). For immunostaining, sections were deparaffinized
in xylene, passed through decreasing concentrations of ethanol,
washed in phosphate-buffered saline (PBS), and submerged for
30 min in 0.3% hydrogen peroxide. After washing with PBS,
sections were incubated for 30 min in bovine testicular
hyaluronidase (33 U/ml; Sigma, St. Louis, MO), washed with
PBS, and further incubated with 1% bovine serum albumin
(blocking buffer). Sections were then incubated with a mono-
clonal anti-bovine type I collagen IgG (Sigma), an anti-bovine
type II collagen IgG (Developmental Studies Hybridoma Bank,
Ames, IA), or a monoclonal anti-aggrecan (Serotec, Oxford,
UK). The primary antibody was detected with a Vectastain Elite
ABC kit (Vector Laboratories, Burlingame, CA), using di-
aminobenzidine as the chromogen. Positive controls included
bovine articular cartilage with vascular structures (for types I
and II collagen and aggrecan) and rat skin (for collagen type
I). Negative controls included omission of the primary antibody,
rat skin (for collagen type II and aggrecan), and bovine articu-
lar cartilage (for collagen type I).
Morphometric measurements and 
biochemical evaluation
Construct dimensions were measured from safranin O-
stained histological sections, using computer-based image anal-
ysis as previously described (Martin et al., 1999). Briefly, 
low-magnification phase-contrast images of the whole cross-
sections of tissue samples were acquired by a solid-state CCD
camera (Hitachi, Tokyo, Japan) mounted on an inverted mi-
croscope (Diaphot; Nikon, Melville, NY), digitized by an LG-
3 frame grabber (Scion, Frederick, MD) into a Macintosh 7100,
and analyzed with the NIH Image public domain program NIH
1.59. For biochemical evaluations, constructs were lyophilized,
digested for 16 hr at 56°C with protease K (1 mg/ml; Sigma)
solution in 50 mM Tris–1 mM EDTA–1 mM iodoacetamide,
using 1 ml of enzyme solution per 4–10 mg sample dry weight
(Freed et al., 1998). DNA was measured by the Hoechst 33258
assay, using a QM-1 spectrofluorometer (Photon Technology
International, South Brunswick, NJ) (Kim et al., 1988). Gly-
cosaminoglycans were measured spectrophotometrically
(PerkinElmer, Norwalk, CT), using dimethylmethylene blue
dye and bovine chondroitin sulfate as a standard (Serva, Darm-
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FIG. 1. Model system. Chondrocytes were isolated from the articular surface of bovine radiocarpal joints, placed in monolayer
culture, and transfected after 3–4 days with a lipid-based system. After 1 day, transfected chondrocytes were dissociated from
the culture vessel and dynamically seeded onto biodegradable polymer scaffolds. After 2 days, the seeded constructs were trans-
ferred to rotating bioreactors and cultured for 28 days in basal medium, followed by an additional 10 days in vivo (in nude mice)
or in vitro (in bioreactors).
stadt, Germany) (Farndale et al., 1986). Total collagen was de-
termined from the measured hydroxyproline content after acid
hydrolysis and reaction with p-dimethylaminobenzaldehyde
and choramine-T (Woessner, 1961), using a hydroxyproline-to-
collagen ratio of 1:10 (Hollander et al., 1994). To determine
the biosynthesis rates of protein and proteoglycan, constructs
(n 5 6 per group) were individually radiolabeled in 12-well
plates, using 1 ml of basal medium containing [3H]proline
(15–20 mCi/ml) and [35S]sulfate (7.5–25 mCi/ml; New England
Nuclear, Boston, MA), as previously described (Freed et al.,
1998). Briefly, dishes were placed on an orbital shaker and in-
cubated for 18 hr at 37°C in a humidified atmosphere with 10%
CO2. Each construct was rinsed four times for 20 min with PBS
(2 ml/rinse), frozen, lyophilized, and digested with papain
(0.125 mg/ml; Sigma) in 100 mM phosphate buffer with 10 mM
EDTA and 10 mM cysteine for 16 hr at 60°C. Aliquots of 200
ml were transferred to scintillation vials and counted in 4 ml of
Cytoscint (ICN, Costa Mesa, CA) in a b counter (Packard In-
struments, Meriden, CT).
IGF-I protein analysis
Constructs harvested from bioreactors at 10 days posttrans-
fection were individually incubated in 24-well plates for 24 hr
in 1 ml of basal medium. Medium collected from these dish
cultures as well as medium sampled from the bioreactors were
stored at 280°C. To determine IGF-I production, conditioned
medium was subjected to a three-step acid–acid–ethanol ex-
traction of binding proteins and analyzed by a radioimmunoas-
say with a detection limit of 20 ng/ml (Nichols Institute, San
Juan Capistrano, CA).
Biomechanical testing
Constructs (n 5 3 or 4 per group) were equilibrated for 1 hr
at room temperature in PBS supplemented with penicillin (100
U/ml), streptomycin (100 mg/ml), and proteinase inhibitors (1
mM phenylmethylsulfonyl fluoride, 2 mM disodium EDTA, 5
mM benzamidine-HCl, 10 mM N-ethylmaleimide), and cored
into 3-mm-diameter, 2-mm-thick disks. Each specimen was
mounted in a cylindrical confining chamber connected to a
servo-controlled mechanical spectrometer (Dynastat; Imass,
Hingham, MA), and compressed under a porous polyethylene
platen. The initial strain of 10% was sequentially increased in
5% increments up to a maximum of 35%. After stress relax-
ation, the equilibrium stress was measured and the equilibrium
modulus was determined from the slope of the linear regres-
sion fit of the stress–strain correlation (Frank and Grodzinsky,
1987; Vunjak-Novakovic et al., 1999).
Subcutaneous implantation
The animal protocol was approved by the Massachusetts In-
stitute of Technology (Cambridge, MA) Committee on Animal
Care. Constructs (n 5 6 per group) were sampled from biore-
actors 4 weeks posttransfection, implanted in dorsal subcuta-
neous pouches in immunocompromised mice (NIH Swiss nude,
25- to 30-g males; Taconic [Germantown, NY] or Charles River
[Cambridge, MA]) and harvested after 10 days of implantation.
Explants were assayed for reporter gene expression and histo-
logical appearance.
Statistical analysis
We performed four independent sets of experiments, in-
volving a total of 125 constructs engineered with bovine artic-
ular chondrocytes obtained from 26 radiocarpal joints. Data are
expressed as averages6 SD and were analyzed by two-way
analysis of variance (ANOVA). A two-tailed p , 0.05 was con-
sidered statistically significant.
RESULTS
Northern analysis of transfected bovine 
articular chondrocytes
Northern hybridization with a human IGF-I DNA probe of
total cellular RNA isolated from chondrocytes transfected with
the IGF-I plasmid expression vector (pCMVhIGF-I) revealed a
broad band spanning a range of ,1.2 to 1.6 kb. These tran-
scripts were not detectable in RNA from lacZ-transfected chon-
drocytes. The transcripts likely represent two mRNA popula-
tions of ,1.3 and 1.5 kb generated by the alternative usage of
the two polyadenylation sites present in the construct, both of
which are translated to the same mature IGF-I polypeptide (Fig.
2) (Eming et al., 1996).
Transgene expression and chondrogenesis
To determine the level of recombinant IGF-I protein pro-
duction, conditioned medium produced by the transfection of
monolayers of bovine articular chondrocytes with pCMVhIGF-
I was analyzed by IGF-I radioimmunoassay. Mean IGF-I pro-
duction was approximately 80 ng per 1 3 107 cells, consistent
with our previous studies (836 22 ng per 1 3 107 cells; Madry
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FIG. 2. Northern analysis. Total cellular RNA from chon-
drocytes transfected with the hIGF-I expression plasmid vector
(lane 1) and with the lacZ expression plasmid vector (lane 2)
was hybridized to a DNA probe corresponding to the hIGF-I
cDNA in the transgene and subsequently rehybridized to a
bovine GAPDH DNA probe. The positions of the 2.37- and
1.35-kb RNA markers are indicated by arrows.
et al., 2001b). Transgene expression, determined by X-Gal
staining of lacZ constructs, was maintained over 28 days in vitro
followed by 10 more days either in vitro or in vivo. X-Gal-pos-
itive cells were distributed throughout the constructs until the
end point of this study (day 38) (insets, Fig. 3a–d). The corre-
sponding intensity and uniformity of distribution of safranin O
stain in constructs based on IGF-I-transfected chondrocytes pro-
gressively increased over the period of bioreactor culture (Fig.
3a–c), and continued to increase over 10 days of in vivo im-
plantation (Fig. 3b and d). Explanted constructs appeared car-
tilaginous over their entire cross-sections, and were surrounded
only by a thin fibrous capsule characteristic for subcutaneous
implantation (data not shown). The intensity of safranin O stain-
ing was higher after 28 days of in vitro culture followed by 10
days in vivo (Fig. 3d) than after 38 days in vitro (Fig. 3c).
Structure and composition of engineered 
cartilaginous constructs
After dissociation from the cell culture dish, chondrocyte via-
bility was above 90% for all groups (data not shown). The frac-
tions of chondrocytes that attached to the scaffolds were compa-
rable for the nontransfected, lacZ, and IGF-I constructs (80.86
8.2, 78.06 9.8, and 77.66 8.0%, respectively; n5 3, p. 0.05).
There was no difference in the postseeding cell viability (94.96
2.4, 95.26 3.4, and 94.86 1.2%, respectively, n5 3, p. 0.05),
suggesting that the transfection procedure and transgene products
had no adverse effect on chondrocyte viability and attachment.
Over the course of bioreactor culture, the initial wet weight
(786 14 mg) and size (5 mm in diameter3 2 mm thick) of non-
transfected and lacZ constructs decreased significantly and pro-
gressively. This suggests that, in these controls, tissue accumula-
tion resulting from the biosynthetic activity of their cells was
exceeded by scaffold degradation (Fig. 4a and Table 1). In con-
trast, the wet weight and size of IGF-I constructs were maintained
throughout the period of bioreactor cultivation and after 28 days
were significantly higher than for either control (Fig. 4a and Table
1). After 28 days of cultivation, transgene expression was main-
tained as evidenced by X-Gal staining of lacZ constructs (Fig.
4b). The corresponding IGF-I constructs stained more intensely
with safranin O than either control (Figs. 4c and 5a–c). In con-
structs from all groups, immunohistological evaluation demon-
strated the absence of type I collagen (Fig. 5d–f) and the presence
of type II collagen (Fig. 5g–i) and aggrecan (Fig. 5k–m).
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FIG. 3. Transgene expression and progression of chondrogenesis. (a) Cell–polymer constructs 2 days after seeding, (b) con-
structs cultured for 28 days, (c) constructs cultured for 38 days, and (d) constructs cultured for 28 days and implanted in nude
mice for 10 days, all from the IGF-I group, stained with safranin O. Insets show the corresponding lacZ constructs, stained with
X-Gal. Original magnification (all images and insets): 3200.
FIG. 4. Development of genetically modified cartilaginous constructs (a) Wet weights of engineered cartilaginous constructs
based on chondrocytes transfected with lacZ (open circles), the human IGF-I (solid circles), or nontransfected chondrocytes (open
squares) over 28 days of in vitro cultivation. The number of samples was n 5 10 for each group. (b) X-Gal staining and (c)
safranin O staining of representative construct sections (top, IGF-I; middle, nontransfected; bottom, lacZ) on day 28 posttrans-
fection.
IGF-I constructs contained increased amounts of DNA, gly-
cosaminoglycans and collagen as compared with either control
(Table 1), but the biochemical compositions remained subnormal
for all groups. Importantly, the amount of glycosaminoglycans per
unit DNA in IGF-I constructs (14.36 1.2 mg/mg) was markedly
higher than for the corresponding constructs cultured in serum-
supplemented medium (3.256 0.22; Vunjak-Novakovic et al.,
1999), or native cartilage (9.16 3.3; Vunjak-Novakovic et al.,
1999). The amount of collagen per unit DNA in IGF-I constructs
(176 0.9 mg/mg) was also higher than for the corresponding con-
structs cultured in serum-supplemented medium (4.186 0.2
[Riesle et al., 1998; Vunjak-Novakovic et al., 1999]) or native
cartilage (10.56 2.3; Vunjak-Novakovic et al., 1999).
Biosynthetic activity and mechanical properties 
of engineered constructs
Incorporation rate of [35S]sulfate per microgram of DNA, an
index of glycosaminoglycan synthesis, was markedly higher for
IGF-I constructs than for either nontransfected or lacZ con-
structs (Table 1). The incorporation rate of [3H]proline per mi-
crogram of DNA, an index of protein synthesis, was compara-
ble for the three groups (Table 1). After 28 days of culture, the
medium level of glucose was approximately 30% lower and the
medium level of lactate was approximately 80% higher in biore-
actors containing IGF-I constructs than in either control group
(Table 1). IGF-I was not detected in the culture medium for any
group at any time during cultivation.
The equilibrium modulus of IGF-I constructs was 1266 52
kPa. This value was 4-fold higher than that measured for either
control (Table 1), and slightly but not significantly lower than
that measured for constructs cultured in medium supplemented
with 10% serum (Vunjak-Novakovic et al., 1999). For compar-
ison, the equilibrium moduli reported for bovine calf cartilage
range from 270 kPa for the articular surface (Chen et al., 2001)
to approximately 700–900 kPa for the deep zone (Freed et al.,
1997; Chen et al., 2001), with 470 kPa reported as the mean ho-
mogeneous value (Mow and Ratcliffe, 1997; Chen et al., 2001).
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TABLE 1. STRUCTURAL AND FUNCTIONAL PARAMETERS OF ENGINEERED
CARTILAGE AFTER 4 WEEKS OF BIOREACTOR CULTIVATION a
Construct parameter
measured after 4 weeks of
Construct
bioreactor cultivation lacZ IGF-I Nontransfected
Construct structure
Wet weight (mg/construct) 26.56 2.10 67.76 10.8 29.06 8.50
(n 5 10, p , 0.001) (n 5 10) (n 5 10, p , 0.001)
Dry weight (mg/construct) 2.26 0.4 5.86 1.1 2.86 0.4
(n 5 10, p , 0.001) (n 5 10) (n 5 10, p , 0.001)
Diameter (mm) 5.66 0.1 6.56 0.2 5.36 0.2
(n 5 10, p , 0.001) (n 5 10) (n 5 10, p , 0.001)
Water (% wet weight) 92.56 1.00 91.36 0.90 88.76 3.50
(n 5 6, p , 0.05) (n 5 5) (n 5 6, p . 0.05)
DNA (mg/construct) 48.86 7.00 74.36 11.5 38.46 7.00
(n 5 6, p 5 0.001) (n 5 5) (n 5 6, p 5 0.001)
Glycosaminoglycans 96.36 15.3 1068.66 239.60 133.36 51.10
(mg/construct) (n 5 6, p 5 0.001) (n 5 5) (n 5 6, p , 0.001)
Glycosaminoglycans 2.06 0.2 14.36 1.20 3.46 0.9
(mg/mg DNA) (n 5 6, p , 0.001) (n 5 5) (n 5 6, p , 0.001)
Collagen (mg/construct) 0.66 0.1 1.36 0.2 0.56 0.1
(n 5 6, p , 0.001) (n 5 2) (n 5 6, p , 0.001)
Collagen (mg/mg DNA) 11.66 1.30 17.06 0.90 14.16 1.90
(n 5 6, p , 0.001) (n 5 5) (n 5 6, p 5 0.015)
Construct fashion
[35S]Sulfate incorporation 2.36 0.6 9.46 1.0 3.86 0.9
(cpm/mg DNA/16 hr) (n 5 6, p , 0.001) (n 5 5) (n 5 6, p , 0.001)
[3H]Proline incorporation 38.9 6 8.3 45.46 6.10 43.66 7.10
(cpm/mg DNA/16 hr) (n 5 6, p , 0.05) (n 5 5) (n 5 6, p . 0.05)
Glucose in medium (mg/cm3) 3.226 0.07 2.216 0.52 3.116 0.20
(n 5 2, p . 0.05) (n 5 2) (n 5 2, p . 0.05)
Lactate in medium (mg/cm3) 0.9986 0.070 1.806 0.49 1.046 0.12
(n 5 2, p . 0.05) (n 5 2) (n 5 2, p . 0.05)
Equilibrium modulus (kPa) 356 33 1266 520 306 40
(n 5 3, p , 0.05) (n 5 4) (n 5 3, p , 0.03)
aValues in parentheses indicate the number of samples per group followed by the p value for comparing the respective con-
trol group with IGF-I constructs. Data represent averages6 standard deviation.
DISCUSSION
Gene transfer of human IGF-I cDNA into articular chon-
drocytes markedly improved the structural and functional prop-
erties of tissue-engineered cartilage. Transgene expression was
maintained over 28 days of in vitro cultivation followed by an
additional 10 days either in vitro or in vivo. IGF-I gene trans-
fer enhanced chondrogenesis in engineered constructs, as evi-
denced by significant increases in construct size and weight,
biosynthesis and accumulation of cartilaginous tissue compo-
nents, and mechanical properties. This is, to the best of our
knowledge, the first report of the application of gene transfer
to modulate the chondrogenesis in tissue-engineered cartilage.
We utilized a model system based on genetically modified cells,
three-dimensional biodegradable scaffolds, and a bioreactor de-
signed to support tissue development from isolated cells under
controlled environmental conditions.
The human IGF-I gene served as a model to demonstrate the
potential benefits of gene transfer for tissue engineering. In
these studies, we chose a lipid-based transfer system that has
been previously shown to efficiently transfect articular chon-
drocytes (Madry and Trippel, 2000). To avoid phenotypic drift
(von der Mark et al., 1977), the transfection protocol utilized a
brief monolayer culture without passaging (Madry and Trippel,
2000; Madry et al., 2001a) The fibrous polyglycolic acid scaf-
folds were specifically designed for cartilage tissue engineer-
ing and have been well characterized in our previous studies
(Freed et al., 1994). These scaffolds were dynamically seeded
with cells, using a method that results in an essentially 100%
yield of cell attachment, high initial cell density, and spatially
uniform cell distribution (Vunjak-Novakovic et al., 1998). The
resulting constructs were cultured in bioreactors in serum-free
medium, under hydrodynamic conditions that were previously
found optimal for in vitro chondrogenesis (Freed et al., 1998;
Vunjak-Novakovic et al., 1999). We chose the model of sub-
cutaneous implantation as a simple method to test for the main-
tenance of transgene expression in vivo (Vacanti et al., 1991;
Freed et al., 1993; Krueger et al., 1997).
Constructs from all three groups were characterized as carti-
laginous with respect to tissue morphology and composition of
the extracellular matrix, including in particular the presence of
glycosaminoglycans, aggrecan, and type II collagen, and the ab-
sence of type I collagen. The confined-compression equilibrium
modulus for IGF-I constructs was 4-fold higher than that for
nontransfected and lacZ-transfected controls. This result is con-
sistent with the respective biochemical construct compositions
and previously reported structure–function relationships for en-
gineered cartilage constructs (Vunjak-Novakovic et al., 1999)
and native cartilage explants exposed to exogenous human IGF-
I (Sah et al., 1996). Further studies are needed to determine
whether the observed effects are a result of sustained rather than
early or transient expression of IGF-I, and to measure the frac-
tions of transfected cells over the course of in vitro cultivation.
Gene transfer of human IGF-I increased the rate of [35S]sul-
fate incorporation into glycosaminoglycans after 4 weeks in cul-
ture, but did not appear to increase the rate of [3H]proline in-
corporation into protein, suggesting that IGF-I differentially
augmented synthesis of these matrix constituents at this time
point. The observed anabolic effects of IGF-I on engineered
cartilage are consistent with previously reported effects of IGF-
I on [3H]proline and [35S]sulfate incorporation in articular chon-
drocytes (Trippel, 1995), articular cartilage explants (Sah et al.,
1994), and articular cartilage in vivo (Nixon et al., 1999). For
constructs engineered with nontransfected bovine articular
chondrocytes, the incorporation rates of [35S]sulfate and
[3H]proline in 4-day constructs were comparable to those mea-
sured for freshly explanted cartilage, but decreased by approx-
imately 40% over 6 weeks of cultivation (Freed et al., 1998),
which may suggest that some of the effects of IGF-I were more
pronounced at early stages of cultivation. Constructs and native
cartilage contained similar amounts of [3H]proline relative to
the total amount of incorporated 3H, indicating that proline hy-
droxylation did not appear to limit the rate of collagen synthe-
sis (Freed et al., 1998).
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FIG. 5. Expression of cartilage-specific tissue markers. Rep-
resentative histologic sections of genetically modified carti-
laginous constructs on day 28 from the lacZ group (left), the
IFG-I group (middle), and the nontransfected group (right)
stained with safranin O (a–c), a monoclonal anti-type I colla-
gen antibody (d–f), a polyclonal anti-type II collagen antibody
(g–i), or a monoclonal aggrecan antibody (k–m). Pictures were
taken with the same photographic parameters, including the
same light intensity. Original magnification (all images): 3200.
Constructs cultured in serum-free medium contained wet
weight fractions of DNA, glycosaminoglycans, and collagen that
were all below the corresponding values measured for constructs
cultured in medium supplemented with 10% fetal bovine serum
(Vunjak-Novakovic et al., 1999). IGF-I constructs contained
amounts of glycosaminoglycans and total collagen per unit DNA
that were markedly higher than in either control group (Table 1),
constructs cultured in serum-supplemented medium, or freshly
explanted native cartilage (Vunjak-Novakovic et al., 1999). Al-
though IGF-I transfection substantially augmented the biochem-
ical and biomechanical construct properties (Table 1), it did not
bring them to normal levels measured for native cartilage.
The enhancement of the per-cell production of extracellular
matrix components by the sustained, spatially defined overex-
pression of IGF-I may not have been fully utilized due to the
low construct cellularity, which in turn may be caused by the
lack of specific serum components in the serum-free culture
medium. Studies have demonstrated that multiple factors, rather
than a single growth factor at a time, are required to achieve
rapid chondrogenesis in this model of cartilage tissue engi-
neering (Gooch et al., 2001, 2002; Martin et al., 2001; Pei et
al., 2001; Blunk et al., 2002). Future studies thus need to iden-
tify optimal combinations of genes that modulate and enhance
in vitro chondrogenesis. Also, because the environment of the
joint differs from that in a bioreactor and may contribute to the
properties of the tissue, the application of such constructs to in
vivo models may further modulate their properties.
The maintenance of transgene expression in engineered con-
structs in vivo forms a basis for further investigations of articu-
lar cartilage repair using genetically modified cartilaginous con-
structs. The long-term availability of the plasmid DNA vector
within an engineered construct in an articular joint is a prereq-
uisite for the stimulation of chondrogenesis over a prolonged pe-
riod of time. For such applications, the cytomegalovirus (CMV)
promoter-enhancer used in the present study may be replaced
with regulatory elements that are tissue specific or responsive to
physiological conditions (Kitamura and Kawachi, 1997).
In contrast to monolayer cultures of isolated, transfected
chondrocytes (Madry and Trippel, 2000; Smith et al., 2000;
Brower-Toland et al., 2001), the three-dimensional cartilagi-
nous constructs analyzed in the present study did not release
detectable amounts of IGF-I into the culture medium. This dif-
ference may reflect the retention of IGF-I within the constructs
due to the presence of IGF-I-binding proteins, as has been
shown for native articular cartilage (Sah et al., 1994). It is there-
fore possible that the observed effects are a result of the stim-
ulus provided by an early and transient IGF-I expression. The
absence of secreted IGF-I would be desirable in a clinical set-
ting, in order to avoid systemic effects of the overexpressed
growth factor.
One of the problems that currently limit ex vivo gene ther-
apy of cartilaginous lesions is the loss of transplanted cells 
(O’Driscoll, 1998) and a decline in the transgene expression
over time (Kang et al., 1997; Doherty et al., 1998). Also, the
dense cartilaginous matrix was shown to limit the efficiency of
direct in vivo gene transfer (Ikeda et al., 1998). Genetically
modified cartilaginous constructs overexpressing a growth fac-
tor gene may be used as a tissue substitute that simultaneously
provides a stimulus for repair. The transplantation of such con-
structs may be advantageous compared with either gene ther-
apy or tissue engineering alone.
In summary, gene transfer of a human IGF-I cDNA enhanced
structural and functional properties of engineered cartilage.
Gene expression was maintained throughout the duration of the
study, over 4 weeks in vitro followed by an additional 10 days
either in vitro or in vivo. The observed enhancement of chon-
drogenesis by spatially defined overexpression of human 
IGF-I suggests that cartilage tissue engineering based on ge-
netically modified chondrocytes may be advantageous as com-
pared with either gene transfer or tissue engineering alone. This
new concept can potentially enhance the clinical utility of en-
gineered cartilage, and provide physiologically relevant mod-
els for controlled studies of the effect of single genes on the
regulation of chondrogenesis. Experiments of this kind could
be extended to a variety of regulatory molecules in order to
identify mechanisms that influence cartilage development. Fur-
ther studies are needed to evaluate genetically modified carti-
laginous constructs in clinically relevant models in vivo.
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